Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.53 |
| ▸ | PIK3CD known ✓ | O00329 | 1/20 | 0.44 |
| ▸ | HTR6 known ✓ | P50406 | 2/20 | 0.42 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.42 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | RHEB | Q15382 | 7/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29670267 | 0.98 | AHR (0.56) | AHRTDP1PARP1RECQLALDH1A1 | |
| SCHEMBL113992 | 0.98 | AHR (0.56) | AHRTDP1PARP1RECQLALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL9935854 | 0.95 | AHR (0.54) | AHRTDP1PARP1RECQLALDH1A1 | |
| Iodide SCHEMBL29022372 | 0.95 | AHR (0.54) | AHRTDP1PARP1RECQLALDH1A1 | |
| Methylene Chloride SCHEMBL27828016 | 0.90 | TDP1 (0.48) | AHRTDP1PARP1RECQLALDH1A1 | |
| SCHEMBL27579654 | 0.79 | HTR1A (0.41) | AHRTDP1PARP1RECQLALDH1A1 | |
| Tert-Butyl Formate SCHEMBL28030918 | 0.78 | TDP1 (0.42) | AHRTDP1PARP1RECQLRHEB | |
| Ethoxycarbonyl Group SCHEMBL27965810 | 0.77 | PARP1 (0.41) | AHRTDP1PARP1RECQLRHEB | |
| Quinoline SCHEMBL27756079 | 0.77 | ALDH1A1 (0.50) | AHRTDP1PARP1RECQLALDH1A1 | |
| SCHEMBL28126424 | 0.77 | PARP1 (0.41) | AHRTDP1PARP1RECQLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119018891-A | Method for preparing activated carbon by using crop straw as raw material and application thereof | 福建省鑫森炭业股份有限公司 | 2024-11-26 | — | — | CN | claimed |
| CN-119018891-A | Method for preparing activated carbon by using crop straw as raw material and application thereof | 福建省鑫森炭业股份有限公司 | 2024-11-26 | — | — | CN | disclosed |
| EP-1036058-B1 | ADAMANTANE DERIVATIVES | ASTRAZENECA UK LTD (GB) | 2003-03-12 | — | — | EP | disclosed |
| CN-1093122-C | Piperazine derivatives as 5-HT1A antagonists | WYETH JOHN & BROTHER LTD (GB) | 2002-10-23 | — | — | CN | disclosed |
| US-6242470-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS, ANTIALLERGENS; IRRITABLE BOWEL SYNDROME; AMIDATION | ASTRAZENECA AB (SE) | 2001-06-05 | — | — | US | disclosed |
| EP-1036058-A1 | ADAMANTANE DERIVATIVES | AstraZeneca UK Limited (GB) | 2000-09-20 | — | — | EP | disclosed |
| US-6093716-A | Substituted 2-pyrimidineamines and processes for their preparation | CELLTECH THERAPEUTICS, LIMITED (GB) | 2000-07-25 | — | — | US | disclosed |
| CN-1048985-C | As 5-HT1APiperazine derivatives of antagonists | WYETH JOHN & BROTHER LTD (GB) | 2000-02-02 | — | — | CN | disclosed |
| CN-1227841-A | Piperazine derivatives as 5-HT1A antagonists | WYETH JOHN & BROTHER LTD (GB) | 1999-09-08 | — | — | CN | disclosed |
| EP-0929549-A1 | SUBSTITUTED 2-PYRIMIDINEAMINES, THEIR PREPARATION AND THEIR USE AS PROTEINE KINASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-07-21 | — | — | EP | disclosed |
| WO-1999029660-A1 | ADAMANTANE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 1999-06-17 | — | — | WO | disclosed |
| WO-1998011095-A1 | SUBSTITUTED 2-PYRIMIDINEAMINES, THEIR PREPARATION AND THEIR USE AS PROTEINE KINASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1998-03-19 | — | — | WO | disclosed |
| CN-1149873-A | As 5-HT1APiperazine derivatives of antagonists | WYETH JOHN & BROTHER LTD (GB) | 1997-05-14 | — | — | CN | disclosed |